Search clinical trials for: AMG 133

Total 4600 results

Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Inflammatory Disease

New Zealand
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Amgen

Terminated

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Schizophrenia

United States, France, United Kingdom, Malaysia, Poland, Czech Republic
Amgen

Terminated

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus

United States
Amgen

Completed

Phase II Study to Evaluate the Efficacy of AMG 317

Asthma
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
NantCell, Inc.

Terminated

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Sarcoma | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Metastatic Cancer | Solid Tumors | Locally Advanced
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing Bionovo Medicine Development Co., Ltd.

Completed

A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

Allergy

China
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Amgen

Completed

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Active, not recruiting

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States, Belgium, Austria, Singapore, Taiwan, Japan
AstraZeneca
Parexel

Recruiting

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)

Asthma

United States
Amgen

Completed

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Asthma

Canada
Amgen

Completed

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

Healthy Volunteers | Atopic Dermatitis
Cytokinetics

Completed

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Healthy Volunteer

Japan
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands
Pfizer

Terminated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Metastatic Pancreatic Adenocarcinoma | BRAF Mutated Melanoma

United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Amgen

Completed

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
Amgen

Completed

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Cardiovascular Disease

United States, Australia, Netherlands, Canada, Denmark, Iceland, Japan
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
MedImmune LLC
Amgen

Completed

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

United States, Sweden, France, United Kingdom
Whanin Pharmaceutical Company

Enrolling by invitation

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

Schizophrenia

Korea, Republic of
National Cardiovascular Center Harapan Kita Hospital...

Completed

Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery

Coronary Artery Disease

Indonesia
Bausch Health Americas, Inc.

Terminated

AMG 827 in Subjects With Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Bulgaria, Denmark, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, South Africa, Sweden, United Kingdom
Amgen

Terminated

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Heart Failure | Healthy Volunteer

France, United States, Netherlands, New Zealand, Germany, Australia, Poland, Canada, Singapore
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States, Canada
Amgen

Recruiting

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Taiwan, Germany, Spain, Turkey, Greece, Japan, Switzerland, Denmark, Korea, Republic of, Austria, Italy, Netherlands, Poland, Romania, Belgium, Argentina, Bulgaria, Czechia, Finland, Hungary, Mexico, Latvia, France, Canada, Slovaki...
Amgen

Completed

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

Osteoporosis

United States
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis RA

United States, Poland, Germany, Bulgaria, Spain
Robert Bok, MD, PhD
National Cancer Institute (NCI)

Recruiting

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Adult Gliomas, Mixed

United States
Amgen

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)

Osteopenia | Postmenopausal
AmMax Bio, Inc.

Completed

A Study of AMG 820 in Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States
Amgen

Completed

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

Osteopenia
Amgen

Completed

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis (BRIDGE)

Osteoporosis in Men

United States, Belgium, Colombia, Czechia, Denmark, Japan, Mexico, Poland, Russian Federation, Switzerland
Amgen

Completed

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Systemic Lupus Erythematosus

United States
Amgen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Crohn's Disease | Ulcerative Colitis

United States, Australia

Search clinical trials for: AMG 133

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations